Form 4: Evoke Pharma Director Kenneth J. Widder Acquires Stock Options
SEC Form 4 Filing
Director Kenneth J. Widder acquired stock options in Evoke Pharma, Inc. on May 22, 2024.
Summary
- Kenneth J. Widder, a director of Evoke Pharma, Inc., reported a transaction involving derivative securities.
- On May 22, 2024, Widder acquired stock options for 14,250 shares of common stock at an exercise price of $0.451.
- The options vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.
- Following the transaction, Widder directly owns derivative securities for 14,250 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard regulatory filing reporting an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option acquisition |
| 05/24/2024 | Date of Form 4 filing |
| 05/21/2034 | Expiration date of the stock options |
Keywords
Evoke Pharma, Director, Stock Options, Form 4, Beneficial Ownership, Securities, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.